Filter by date
The Second Phase of Akrikhin’s Investment Program is completed: Commissioning of soft forms production line in accordance with GMP
Akrikhin has completed the Second Phase of its Investment Program – reorganization of production of soft forms. From now on, the Company’s production of soft forms entirely corresponds to GMP Standards. Investment under the project reached 120 million RF Rubles.
The licensed partnership between AKRIKHIN and Bristol-Myers Squibb Company is the longest partnership project in the history of the Russian pharmaceutical industry.
AKRIKHIN and MSD in Russia sign agreement to produce key MSD medicines for Russia
AKRIKHIN, a leading pharmaceutical manufacturer in Russia has signed an agreement on manufacturing and packaging with MSD in Russia. Under the terms of the agreement AKRIKHIN, using its manufacturing sites in Moscow, will produce six key MSD products, accounting for different dosages and formulations, for the Russian market.
AKRIKHIN has marketed rapid-acting insulin
In June, “AKRIKHIN” has extended its antidiabetic portfolio. The novel drug (INN repaglinide) is referred to peroral medicines for the treatment of type 2 diabetes mellitus stimulating insulin production. The drug is launched by “AKRIKHIN” in the Russian market within the company’s strategy aimed at provision of patients with affordable drugs for the treatment of socially significant diseases. The drug is included in the Essential Drug List.
Akrikhin ranked 2nd in terms of influence in a rating of the Russian manufacturing pharmaceutical companies
Akrikhin ranked 2nd in “Rating of influence of Russian pharmaceutical market participants”, The most influential local pharmaceutical manufacturer nomination upon the results of 2011. The rating is an annual joint project by “Pharmexpert. Analytics and consulting” Company and “Pharmaceutical Vestnik (newspaper)”.
AKRIKHIN launched 8 new products in 2011
In 2011 one of the leading Russian pharmaceutical companies AKRIKHIN expanded its product portfolio with 8 new products. Four of the launched products were new brands and referred to the key pharmacotherapeutic lines of focus for AKRIKHIN: diabetes, tuberculosis, dermatology and gynecology, while the others were extension of the lines of the already existing products. New brands appeared in the company portfolio both as a result of in-house developments of the AKRIKHIN’s R&D Centre, and owing to cooperation with the Russian scientific commonwealth and partnership with foreign companies.
Akrikhin invested 389 mln. rubles into production development in 2010-2011
Pharmaceutical company Akrikhin, entering the TOP 5 of the largest Russian pharmaceutical manufacturers, invested 389 mln. rubles into development and modernization of the production complex in 2010-2011. Investments were made within the production complex modernization and reconstruction investment program within the period of 2010 to 2016. The amount of investments in 2010-2016 will total to 960 mln. rubles
Akrikhin extends its cardio portfolio
A new product appeared in the product portfolio of AKRIKHIN – Metozoc (INN - metoprolol succinate) for treatment of cardiovascular diseases. The product is developed by the Company R&D. It is the first generic of metoprolol succinate on the Russian market which has been created based on the technology applied in the original product. The product is included in the List of Essential Medicines.
We use cookies to improve your experience on our site and to show you personalised advertising. By pressing “I AGREE” you accept our cookies policy.
To find out more, go to cookies policy.